权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

RAD51 Inhibitors for Chemotherapy and Radiation Therapy

用于化疗和放疗的 RAD51 抑制剂

基本信息

批准号：
9288157
负责人：
Philip P Connell
金额：
$ 50.1万
依托单位：
UNIVERSITY OF CHICAGO
依托单位国家：
美国
项目类别：
财政年份：
2010
资助国家：
美国
起止时间：
2010-03-16 至 2020-06-30
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/9288157
关键词：
Animal Model Animals Antineoplastic Agents Biochemical Biological Assay Cell Proliferation Cells Cessation of life Chemicals Chicago Chromatin Clinical Trials Computer Simulation DNA Damage DNA Repair DNA biosynthesis Excretory function Exhibits Funding Goals Growth Human Illinois In Vitro Interruption Lead Malignant Neoplasms Measures Mediating Metabolism Metastatic Neoplasm to the Lung Modification Mus Normal tissue morphology Pharmaceutical Chemistry Pharmaceutical Preparations Pharmacology Property Proteins Rad51 recombinase Radiation Radiation therapy Resistance Specificity Structure Structure-Activity Relationship System Telomerase Testing Therapeutic Toxic effect Toxicity Tests Universities Up-Regulation Validation Work absorption base cancer cell cancer subtypes cancer type chemical synthesis chemotherapy drug candidate drug development drug discovery drug testing improved inhibitor/antagonist method development mouse model neoplastic cell novel oncology overexpression pre-clinical prevent protein aggregation protein complex public health relevance senescence small molecule telomere therapy resistant tumor tumor xenograft

项目摘要

DESCRIPTION (provided by applicant): Human malignancies exhibit elevated levels of homologous recombinational (HR) DNA repair proficiency, and we propose that this common feature of malignancy can be exploited therapeutically. We have supported this central hypothesis by developing drug candidates that specifically inhibit HR and overcome the treatment resistance associated with HR up-regulation in cancer cells. Our renewal application builds on these drug discovery efforts and explores novel applications for compounds that target the central HR protein, RAD51. The major hypotheses and goals of this proposal are as follow: First, we will further optimize RAD51-inhibitory compounds with the goal of overcoming tumor resistance to chemotherapy and radiotherapy. We will develop a novel class of compounds that target a specialized activity of RAD51, which we hypothesize will generate less toxicity than more generalized RAD51 inhibitors. Second, we hypothesize that RAD51-inhibitory compounds will inactivate an HR-related mechanism called alternative lengthening of telomere (ALT), which is required for cell proliferation in some cancer subtypes. Since normal human cells exclusively utilize telomerase instead of ALT to maintain their telomeres, we predict that RAD51 inhibition will force ALT-dependent tumor cells into senescence while exerting little or no normal tissue toxicity. Third, we hypothesize that RAD51-stimulatory compounds can specifically promote death in tumor cells that overexpress RAD51. This concept builds on our observations that high levels of RAD51 overexpression cause the formation of toxic RAD51 protein complexes on undamaged chromatin in cancer cells. We have also shown that RAD51-stimulatory compounds accentuate this potentially toxic feature in susceptible cancer types. All of these hypotheses wil be tested using the same three integrated aims, which incorporate a wide range of drug development methods. The first aim will consist of medicinal chemistry optimization and ADMET testing. Specifically, the structures of our lead RAD51-modulating compounds will be optimized via targeted chemical modifications aimed at improving both activity and pharmacologic properties. In the second aim, we will characterize the activity and specificity of RAD51-modulating compounds, using both purified in vitro biochemical systems and cell-based assays. The third aim will validate the highest priority compounds in animal models. RAD51-inhibitory compounds will be tested in two mouse models to confirm that they: 1) sensitize human tumor xenografts to treatment with replication-disrupting chemotherapeutic drugs and/or radiation, and 2) prevent the ALT-dependent cancer cells from forming lung metastases in mice. RAD51- stimulatory compounds will be tested for the ability to shrink susceptible tumor types, by catalyzing toxic RAD51 protein aggregation on undamaged chromatin. Our ultimate goal is to generate two or three drug candidates that are suitable for extended pharmacologic testing and subsequent testing in clinical trials.